Pharmafile Logo

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:
www.researchpartnership.com/news/2016/01/pharma-market-research-report-predictions-for-2016/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...

Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market

Published in eyeforpharma February 2016 by Rachel Howard

Gaining deeper insights within a hard to reach audience

Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Heather Desmet appointed new Head of Living With

We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.

Webinar Recording: The Art of Storytelling in Pharma Market Research

Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...